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There are two fundamental types of epilepsy: -primary generalized epilepsy and -localization-related epilepsy.
• Localization-related epilepsy accounts for 60-75% of all epilepsy cases and has one of three types of partial-onset seizures (POS): 3 -simple partial,
-complex partial, and -partial onset with secondary generalization.
• Appropriate drug selection is multi-faceted and special consideration must be given to tolerability, the potential for drug interactions, and the numerous pharmacokinetic and pharmacodynamic challenges. 4 • Initial antiepileptic drug (AED) therapy is in large part selected based on the patient's seizure/epilepsy type.
-Monotherapy has been the gold standard for several decades based on studies showing equal efficacy, increased tolerability and lower toxicity when compared to therapy with multiple agents. 5,6 -If the first monotherapy agent is ineffective, the patient should be switched to another monotherapy agent using the transitional polytherapy method by which the new agent is initiated and titrated up slowly towards the target dose, while the dose of the baseline drug is reduced over time. -Unless the patient is experiencing a life-threatening reaction, conversion from one monotherapy to another uses coordinated up-and down-titration. 4 • About 35% of patients with epilepsy are considered to be refractory and do not respond to monotherapy. 7, 8 After two failed sequential monotherapy trials, adding an adjunctive agent with a different mechanism of action is recommended. 4 • Approximately 1/3 of patients with partial-onset seizures (POS) are drug resistant and frequently require adjunctive treatment. 9 • Although adjunctively-treated patients are identified in claims data by the concurrent administration of two or more antiepileptic drugs (AEDs), the minimum AED co-administration period has not been established.
•
In order to avoid confounding in claims data analyses, the titration time to maintenance dose of AEDs used in adjunctive therapy needs to be carefully weighed in the classification of adjunctively-treated patients.
BACKGROUND
• To identify the impact of different co-administration periods on the proportion of patients identified as receiving adjunctive therapy within claims data.
OBJECTIVE
• 350 eligible patients married to employees were identified from the initial dataset (through March 30, 2014).
• Based on the length of the overlap period, various scenarios were evaluated for eligibility by direct and indirect components (Table 1) • Using medical and prescription eligibility, the percent classified as receiving adjunctive therapy: -At 30, 45, 60, and 90-days were 41.7%, 39.1%, 38.3% and 34.9%, respectively (Figure 1 ).
-The 90 day overlap period was selected as the appropriate overlap period (Figure 2 ).
RESULTS

CONCLUSIONS
• Retrospective study using the Human Capital Management Systems (HCMS) database of commercially-insured subjects:
-Represents multiple geographically diverse, US-based employers in the retail, service, manufacturing, and financial industries and includes information on more than 2 million employees plus spouses.
-Extracted from claims between January 2001 to June 30, 2014.
-The HCMS database has been used in prior epilepsy research.10
-The data were de-identified to comply with the Health Insurance Portability and Accountability Act and the contractual obligations between HCMS and its employer-contributors. -assigned an index date based on their initial AED use.
-required to have >365 days of continuous eligibility following their index date.
• Using data through March 30, 2014:
-Patients were classified as having adjunctive therapy on the basis of having at least 30, 45, 60, or 90 days of concomitant AED use in the period following their index date.
-The different overlap periods were compared with the literature to yield the correct representation.
• Once the cohorts were identified the database was updated to add information through June 30, 2014. Using the updated database, the following information was generated: 
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• After the addition of data through June 30, 2014: -Descriptive statistics were generated for the two cohorts (Table 2 ) and found the cohorts to be similar.
-The average time to (Figure 3 ): § initiate monotherapy was 17.8 days from the first POS diagnosis, § initiate adjunctive therapy was 56.6 days from the POS diagnosis; and § progress to adjunctive therapy from monotherapy was 41.4 days.
